Influence of Bone Morphogenic Protein 7 (BMP7) on the Progression of Chronic Kidney Disease
DOI:
https://doi.org/10.12970/2310-984X.2014.02.01.1Keywords:
Chronic kidney disease, bone morphogenetic protein 7, disease progression.Abstract
Background-Aims: Chronic kidney disease (CKD) is an important health problem worldwide. TGF (transforming growth factor)-beta and particularly bone morphogenetic protein 7 (BMP7) are held responsible for renal fibrosis. In our study we aimed to evaluate the association between CKD progression and BMP7 levels. Materials and Methods: Our study included 80 patients who are diagnosed with CKD and being followed between January 2008 and December 2010. Progression of CKD was defined as 50% decrease in glomerular filtration rate (GFR), doubling of serum creatinine and initiation of renal replacement therapy. Serum BMP7 levels have been measured initially and at the end of two years follow-up. Results: At the end of the follow-up CKD progression was detected in 18 out of 80 patients (%22.5). Decrease in glomerular filtration rate was found to be correlated with an increase in PTH, phosphorus and a decrease in serum albumin levels. In patients with progressive disease serum BMP7 levels were significantly higher than the ones with stable disease, which were 458±62.3 pg/mL and 360±82.4 pg/mL, respectively. Conclusion: Our results show that the patients with progressive disease have higher BMP7 levels which is a different finding from the previous trials. We speculate that this paradoxal increase may be a compensatory action against the increase in other profibrotic cytokines.References
[1] Dirks JH, de Zeeuw D, Agarwal SK, et al. Prevention of chronic kidney and vascular disease: Toward global health equity-The Bellagio 2004 Declaration. Kidney Int 2005; 98: S1-S6. http://dx.doi.org/10.1111/j.1523-1755.2005.09800.x
[2] Lysaght MJ. Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 2002; 13: S37-S40.
[3] Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 2009; 5: 677- 89. http://dx.doi.org/10.1038/nrneph.2009.173
[4] Nguyen TQ, Goldschmeding R. Bone morphogenetic protein7 and connective tissue growth factor: novel targets for treatment of renal fibrosis? Pharm Res 2008; 25: 2416-26. http://dx.doi.org/10.1007/s11095-008-9548-9
[5] Dudley AT, Lyons KM, Robertson EJ. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev 1995; 9: 2795-807. http://dx.doi.org/10.1101/gad.9.22.2795
[6] Gould SE, Day M, Jones SS, Dorai H. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 2002; 61: 51-60. http://dx.doi.org/10.1046/j.1523-1755.2002.00103.x
[7] Mitu GM, Wang S, Hirschberg R. BMP 7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal Physiol 2007; 293: F1641-8. http://dx.doi.org/10.1152/ajprenal.00179.2007
[8] L De Petris KA, Hruska S, Chiechio H. BMP-7delays podocyte injury due to high glucose. Nephrol Dial Transplant 2007; 22: 3442-50. http://dx.doi.org/10.1093/ndt/gfm503
[9] Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-8. http://dx.doi.org/10.1038/nm888
[10] Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int 1997; 51: 1908-19. http://dx.doi.org/10.1038/ki.1997.260
[11] Almanzar MM, Frazier KS, Dube PH, et al. Osteogenicprotein-1 mRNA expression is selectively modulated afteracute ischemic renal injury. J Am Soc Nephrol 1998; 9: 1456-63.
[12] Simon M, Maresh JG, Harris SE, Hernandez JD, Arar M, Olson MS, Abboud HE. Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney. Am J Physiol 1999; 276: F382-9.
[13] Hruska KA, Guo G, Wozniak M, et al. Osteogenic protein-1 prevents renal fibrogenesis associatedwith ureteral obstruction. Am J Physiol Renal Physiol 2000; 279: F130-43.
[14] Biyikli NK, Tugtepe H, Cakalagaoglu F, Ilki A, Alpay H. Downregulation of the expression of bone morphogeneticprotein 7 in experimental pyelonephritis. Pediatr Nephrol 2005; 20: 1230-6. http://dx.doi.org/10.1007/s00467-005-1927-4
[15] Ogutmen B, Tuglular S, Cakalagaoglu F, Ozener C, Akoglu E. Transforming growth factor-beta1, vascular endothelial growth factor, and bone morphogenic protein-7 expression intacrolimus-induced nephrotoxicity in rats. Transplant Proc 2006; 38: 487-9. http://dx.doi.org/10.1016/j.transproceed.2005.12.048
[16] Tuglular S, Gogas YD, Cakalagaoglu F, et al. Cyclosporine-A induced nephrotoxicity is associated with decreased renal bone morphogenetic protein-7 expression in rats. Transplant Proc 2004; 36: 131-3. http://dx.doi.org/10.1016/j.transproceed.2003.11.018
[17] Zeisberg M, Bottiglio C, Kumar N, et al. Bone morphogenic protein-7inhibits progression of chronic renal fibrosis associated with twogenetic mouse models. Am J Physiol Renal Physiol 2003; 285: F1060-67.
[18] Duranay M, Segall L, Sen N, et al. Bone morphogenic protein-7 serum level decreases significantly in patients with contrast-induced nephropathy. Int Urol Nephrol 2011; 43: 807-12. http://dx.doi.org/10.1007/s11255-010-9871-z
[19] Wang SN, Lapage J, Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2392-9.
[20] Wang S, Chen Q, Simon TC, et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003; 63: 2037-49. http://dx.doi.org/10.1046/j.1523-1755.2003.00035.x
[21] Tacke F, Gabele E, Bataille F, et al. Bone morphogeneticprotein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci 2007; 52: 3404-15. http://dx.doi.org/10.1007/s10620-007-9758-8
